259 related articles for article (PubMed ID: 34831429)
1. The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity.
Anderson KM; Gayer CP
Cells; 2021 Nov; 10(11):. PubMed ID: 34831429
[TBL] [Abstract][Full Text] [Related]
2. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
[TBL] [Abstract][Full Text] [Related]
3. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
4. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation.
Renga B; Mencarelli A; Cipriani S; D'Amore C; Carino A; Bruno A; Francisci D; Zampella A; Distrutti E; Fiorucci S
PLoS One; 2013; 8(1):e54472. PubMed ID: 23372731
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory functions of FXR.
Fiorucci S; Zampella A; Ricci P; Distrutti E; Biagioli M
Mol Cell Endocrinol; 2022 Jul; 551():111650. PubMed ID: 35472625
[TBL] [Abstract][Full Text] [Related]
6. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
8. Chenodeoxycholic Acid (CDCA) Protects against the Lipopolysaccharide-Induced Impairment of the Intestinal Epithelial Barrier Function via the FXR-MLCK Pathway.
Song M; Ye J; Zhang F; Su H; Yang X; He H; Liu F; Zhu X; Wang L; Gao P; Shu G; Jiang Q; Wang S
J Agric Food Chem; 2019 Aug; 67(32):8868-8874. PubMed ID: 31319027
[TBL] [Abstract][Full Text] [Related]
9. Counter-regulatory role of bile acid activated receptors in immunity and inflammation.
Fiorucci S; Cipriani S; Mencarelli A; Renga B; Distrutti E; Baldelli F
Curr Mol Med; 2010 Aug; 10(6):579-95. PubMed ID: 20642438
[TBL] [Abstract][Full Text] [Related]
10. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific function of farnesoid X receptor in liver and intestine.
Zhu Y; Li F; Guo GL
Pharmacol Res; 2011 Apr; 63(4):259-65. PubMed ID: 21211565
[TBL] [Abstract][Full Text] [Related]
12. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
14. The bile acid receptor FXR is a modulator of intestinal innate immunity.
Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
[TBL] [Abstract][Full Text] [Related]
15. Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity.
Biagioli M; Carino A
Handb Exp Pharmacol; 2019; 256():95-108. PubMed ID: 31119464
[TBL] [Abstract][Full Text] [Related]
16. Bile Acids Activated Receptors Regulate Innate Immunity.
Fiorucci S; Biagioli M; Zampella A; Distrutti E
Front Immunol; 2018; 9():1853. PubMed ID: 30150987
[TBL] [Abstract][Full Text] [Related]
17. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.
Villalona G; Price A; Blomenkamp K; Manithody C; Saxena S; Ratchford T; Westrich M; Kakarla V; Pochampally S; Phillips W; Heafner N; Korremla N; Greenspon J; Guzman MA; Kumar Jain A
JPEN J Parenter Enteral Nutr; 2018 Nov; 42(8):1238-1251. PubMed ID: 29701901
[TBL] [Abstract][Full Text] [Related]
18. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
Maran RR; Thomas A; Roth M; Sheng Z; Esterly N; Pinson D; Gao X; Zhang Y; Ganapathy V; Gonzalez FJ; Guo GL
J Pharmacol Exp Ther; 2009 Feb; 328(2):469-77. PubMed ID: 18981289
[TBL] [Abstract][Full Text] [Related]
20. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease.
Stojancevic M; Stankov K; Mikov M
Can J Gastroenterol; 2012 Sep; 26(9):631-7. PubMed ID: 22993736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
